recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)

DBCOND0144294Neoplasms

recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) is the indication for 4 drugs in DrugBank. It is covered by 9 curated, structured indications.

Also known as: Recurrent Head and Neck Squamous Cell Carcinoma · Recurrent Squamous Cell Carcinoma of the Head or Neck · Recurrent Head and Neck Squamous Cell Cancer · Recurrent Squamous Cell Carcinoma of the Head and Neck
Classified under: Neoplasms
Indicated drugs: Cetuximab
Hyaluronidase (human recombinant)
Nivolumab
Pembrolizumab

What you can answer from here — as of October 22, 2026

4Indicated drugsWith each drug's targets and mechanism

Listed above

9Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

62Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account